HO-1/CO system in tumor growth, angiogenesis and metabolism - Targeting HO-1 as an anti-tumor therapy

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 11-22

  Loboda, Agnieszka ^a   Jozkowicz, Alicja ^a   Dulak, Jozef ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Angiogenesis; Carbon monoxide; HO 1 inhibitors; MicroRNAs; Tumorigenesis

Indexed keywords

BILIVERDIN; CARBON MONOXIDE; HEME OXYGENASE 1; IRON; MICRORNA; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; BREAST CANCER; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CATALYSIS; CELL METABOLISM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; HEART INFARCTION; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); NON SMALL CELL LUNG CANCER; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON MONOXIDE; HEME OXYGENASE-1; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84947599247     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.09.004     Document Type: Review

References (150)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285(21):1182-1186.
4. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. U. S. A. 1968, 61(2):748-755.
5. Loboda A., et al. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2008, 10(10):1767-1812.
6. Stocker R., Glazer A.N., Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. U. S. A. 1987, 84(16):5918-5922.
7. Stocker R., et al. Antioxidant activities of bile pigments: biliverdin and bilirubin. Methods Enzymol. 1990, 186:301-309.
8. Stocker R., et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235(4792):1043-1046.
9. Wegiel, B., et al., Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J. Biol. Chem., 2009. 284(32): p. 21369-21378.
10. Gibbs P.E., Tudor C., Maines M.D. Biliverdin reductase: more than a namesake - the reductase, its peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front. Pharmacol. 2012, 3:31.
11. Pae H.O., et al. Role of heme oxygenase in preserving vascular bioactive NO. Nitric Oxide 2010, 23(4):251-257.
12. Tanaka S., et al. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br. J. Cancer 2003, 88(6):902-909.
13. Busserolles J., et al. Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway. Int. J. Biochem. Cell Biol. 2006, 38(9):1510-1517.
14. Ollinger R., et al. Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle 2007, 6(24):3078-3085.
15. Zheng J., et al. Biliverdin's regulation of reactive oxygen species signalling leads to potent inhibition of proliferative and angiogenic pathways in head and neck cancer. Br. J. Cancer 2014, 110(8):2116-2122.
16. Ikeda Y., et al. Bilirubin exerts pro-angiogenic property through Akt-eNOS-dependent pathway. Hypertens. Res. 2015, [Epub ahead of print]. 10.1038/hr.2015.74.
17. Hayashi S., et al. Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme. Circ. Res. 1999, 85(8):663-671.
18. Wen C.P., et al. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin. Cancer Res. 2015, 21(1):193-200.
19. Ching S., et al. Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J. Nutr. 2002, 132(2):303-306.
20. Zucker S.D., Horn P.S., Sherman K.E. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004, 40(4):827-835.
21. Li N., et al. Elevated serum bilirubin levels are associated with improved survival in patients with curatively resected non-small-cell lung cancer. Cancer Epidemiol. 2015, 39(5):763-768.
22. Eisenstein R.S., et al. Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(3):688-692.
23. Baranano D.E., et al. A mammalian iron ATPase induced by iron. J. Biol. Chem. 2000, 275(20):15166-15173.
24. Torti S.V., Torti F.M. Ironing out cancer. Cancer Res. 2011, 71(5):1511-1514.
25. Coffman L.G., et al. Regulatory effects of ferritin on angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(2):570-575.
26. Tesfay L., et al. Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One 2012, 7(7).
27. Torti S.V., Torti F.M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 2013, 13(5):342-355.
28. Lui G.Y., et al. Targeting cancer by binding iron: dissecting cellular signaling pathways. Oncotarget 2015, 6(22):18748-18779.
29. Lane D.J., et al. Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochim. Biophys. Acta 2014, 1845(2):166-181.
30. Gozzelino R., Jeney V., Soares M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010, 50:323-354.
31. Deng R., et al. Inhibition of tumor growth and alteration of associated macrophage cell type by an HO-1 inhibitor in breast carcinoma-bearing mice. Oncol. Res. 2013, 20(10):473-482.
32. Sierra-Filardi E., et al. Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 2010, 215(9-10):788-795.
33. Dulak J., et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008, 117(2):231-241.
34. Yamamoto T., et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat. Commun. 2014, 5:3480.
35. Kozakowska M., et al. Role of heme oxygenase-1 in postnatal differentiation of stem cells: a possible cross-talk with microRNAs. Antioxid. Redox Signal. 2014, 20(11):1827-1850.
36. Was H., Dulak J., Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr. Drug Targets 2010, 11(12):1551-1570.
37. Was H., et al. Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice. Free Radic. Biol. Med. 2011, 51(9):1717-1726.
38. Kozakowska M., et al. Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs. Antioxid. Redox Signal. 2012, 16(2):113-127.
39. Ciesla M., Dulak J., Jozkowicz A. MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. Int. J. Biochem. Cell Biol. 2014, 53:482-492.
40. Marinissen M.J., et al. Inhibition of heme oxygenase-1 interferes with the transforming activity of the Kaposi sarcoma herpesvirus-encoded G protein-coupled receptor. J. Biol. Chem. 2006, 281(16):11332-11346.
41. Martin M.J., et al. The Galpha12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase-1 expression and tumorigenesis. J. Biol. Chem. 2007, 282(47):34510-34524.
42. Mayerhofer M., et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 2004, 64(9):3148-3154.
43. Singh M.M., et al. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 2012, 118(13):3433-3445.
44. Yoshida C., et al. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood 2007, 109(3):1211-1219.
45. Cerny-Reiterer S., et al. Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget 2014, 5(121):1198-1211.
46. Kondo R., et al. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood 2007, 110(2):661-669.
47. Banerjee P., et al. The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett. 2013, 338(2):292-299.
48. McAllister S.C., et al. Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. Blood 2004, 103(9):3465-3473.
49. Birrane G., et al. Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion. Int. J. Oncol. 2013, 42(6):1919-1928.
50. Was H., et al. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am. J. Pathol. 2006, 169(6):2181-2198.
51. Sunamura M., et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003, 6(1):15-24.
52. Nishie A., et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 1999, 5(5):1107-1113.
53. Hirai K., et al. Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int. J. Cancer 2007, 120(3):500-505.
54. Loboda A., Jozkowicz A., Dulak J. Carbonmonoxide: pro- or anti-angiogenic agent? Comment on Ahmad et al. (Thromb Haemost 2015; 113: 329-337). Thromb. Haemost. 2015, 114(20150423).
55. Chan K.H., Ng M.K., Stocker R. Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential. Clin. Sci. (Lond.) 2011, 120(12):493-504.
56. Deshane J., et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J. Exp. Med. 2007, 204(3):605-618.
57. Choi Y.K., et al. Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. J. Biol. Chem. 2010, 285(42):32116-32125.
58. Chin B.Y., et al. Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(12):5109-5114.
59. Sengupta S., et al. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br. J. Pharmacol. 2003, 139(2):219-231.
60. Tertil M., et al. Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1. PLoS One 2014, 9(5).
61. Skrzypek K., et al. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid. Redox Signal. 2013, 19(7):644-660.
62. Gueron G., et al. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol. Cancer Res. 2009, 7(11):1745-1755.
63. Vitek L., et al. Antiproliferative effects of carbon monoxide on pancreatic cancer. Dig. Liver Dis. 2014, 46(4):369-375.
64. Ahmad S., et al. Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb. Haemost. 2015, 113(2):329-337.
65. Wegiel B., Hanto D.W., Otterbein L.E. The social network of carbon monoxide in medicine. Trends Mol. Med. 2013, 19(1):3-11.
66. Arnold J.N., et al. Tumoral immune suppression by macrophages expressing fibroblast activation protein-alpha and heme oxygenase-1. Cancer Immunol. Res. 2014, 2(2):121-126.
67. Andersen M.H., et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J. Clin. Invest. 2009, 119(8):2245-2256.
68. El Andaloussi A., Lesniak M.S. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J. Neuro-Oncol. 2007, 83(2):145-152.
69. Dey M., et al. Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model. J. Neuroimmunol. 2014, 266(1-2):33-42.
70. Hull T.D., Agarwal A., George J.F. The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1. Antioxid. Redox Signal. 2014, 20(11):1770-1788.
71. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8(6):519-530.
72. Riganti C., et al. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic. Biol. Med. 2012, 53(3):421-436.
73. Hishiki T., et al. Carbon monoxide: impact on remethylation/transsulfuration metabolism and its pathophysiologic implications. J. Mol. Med. (Berl.) 2012, 90(3):245-254.
74. De Bock K., et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 2013, 154(3):651-663.
75. Ghesquiere B., et al. Metabolism of stromal and immune cells in health and disease. Nature 2014, 511(7508):167-176.
76. Faller M., et al. Heme is involved in microRNA processing. Nat. Struct. Mol. Biol. 2007, 14(1):23-29.
77. Weitz S.H., et al. Processing of microRNA primary transcripts requires heme in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(5):1861-1866.
78. Hua Z., et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006, 1.
79. Wang S., Olson E.N. AngiomiRs-key regulators of angiogenesis. Curr. Opin. Genet. Dev. 2009, 19(3):205-211.
80. Banerjee P., et al. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J. Biol. Chem. 2011, 286(38):33580-33590.
81. Banerjee P., et al. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J. Biol. Chem. 2012, 287(38):32113-32123.
82. Kim H.P., et al. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J. 2004, 18(10):1080-1089.
83. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 1997, 37:517-554.
84. Sacca P., et al. Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer. Br. J. Cancer 2007, 97(12):1683-1689.
85. Lin Q., et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J. Biol. Chem. 2007, 282(28):20621-20633.
86. Dunn L.L., et al. New insights into intracellular locations and functions of heme oxygenase-1. Antioxid. Redox Signal. 2014, 20(11):1723-1742.
87. Hori R., et al. Gene transfection of H25A mutant heme oxygenase-1 protects cells against hydroperoxide-induced cytotoxicity. J. Biol. Chem. 2002, 277(12):10712-10718.
88. Biswas C., et al. Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2, impacting metabolic and anti-oxidant defenses. J. Biol. Chem. 2014, 289(39):26882-26894.
89. Dennery P.A. Signaling function of heme oxygenase proteins. Antioxid. Redox Signal. 2014, 20(11):1743-1753.
90. Wegiel B., et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 2013, 73(23):7009-7021.
91. Li M.Y., et al. Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis. Eur. Respir. J. 2008, 32(4):911-923.
92. Degese M.S., et al. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer 2012, 77(1):168-175.
93. Gandini N.A., et al. Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. Exp. Mol. Pathol. 2012, 93(2):237-245.
94. Hsu F.F., et al. Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. Oncogene 2015, 34(18):2410-2411.
95. Hill M., et al. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J. 2005, 19(14):1957-1968.
96. Lee W.Y., et al. The induction of heme oxygenase-1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide. Toxicol. Appl. Pharmacol. 2014, 274(1):55-62.
97. Lin C.W., et al. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol. Cancer Ther. 2008, 7(5):1195-1206.
98. Kim D.H., et al. 15-Deoxy-Delta12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis 2009, 30(4):645-654.
99. Nielsen V.G., et al. Plasmatic hypercoagulation in patients with breast cancer: role of heme oxygenase-1. Blood Coagul. Fibrinolysis 2013, 24(8):809-813.
100. Nielsen V.G., Pretorius E. Carbon monoxide: anticoagulant or procoagulant?. Thromb. Res. 2014, 133(3):315-321.
101. Tsai J.R., et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell. Oncol. (Dordr.) 2012, 35(6):461-471.
102. Kim H.R., et al. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 2008, 60(1):47-56.
103. Kuroda H., et al. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 2010, 67(1):31-36.
104. Lee P.J., et al. Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(19):10393-10398.
105. Homma S., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 2009, 15(10):3423-3432.
106. Nuhn P., et al. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol. Cancer 2009, 8:37.
107. Berberat P.O., et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin. Cancer Res. 2005, 11(10):3790-3798.
108. Maines M.D., Abrahamsson P.A. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 1996, 47(5):727-733.
109. Alaoui-Jamali M.A., et al. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009, 69(20):8017-8024.
110. Li Y., et al. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J. Pathol. 2011, 224(1):90-100.
111. Ferrando M., et al. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011, 14(4):467-479.
112. Elguero B., et al. Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Neoplasia 2012, 14(11):1043-1056.
113. Ferrando M., et al. Heme oxygenase-1 (HO-1) expression in prostate cancer cells modulates the oxidative response in bone cells. PLoS One 2013, 8(11).
114. Gueron G., et al. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget 2014, 5(12):4087-4102.
115. Schulz S., et al. Metalloporphyrins - an update. Front. Pharmacol. 2012, 3:68.
116. Grundemar L., Ny L. Pitfalls using metalloporphyrins in carbon monoxide research. Trends Pharmacol. Sci. 1997, 18(6):193-195.
117. Fang J., et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003, 63(13):3567-3574.
118. Metz R., et al. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol. Cancer Ther. 2010, 9(6):1864-1871.
119. La P., et al. Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J. Biol. Chem. 2009, 284(52):36302-36311.
120. Wang S., et al. Zinc protoporphyrin suppresses cancer cell viability through a heme oxygenase-1-independent mechanism: the involvement of the Wnt/beta-catenin signaling pathway. Biochem. Pharmacol. 2013, 85(11):1611-1618.
121. Yang G., et al. Unique effects of zinc protoporphyrin on HO-1 induction and apoptosis. Blood 2001, 97(5):1306-1313.
122. Sahoo S.K., et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 2002, 13(5):1031-1038.
123. Fang J., et al. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int. J. Cancer 2004, 109(1):1-8.
124. Tsukigawa K., et al. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor. Eur. J. Pharm. Biopharm. 2015, 89:259-270.
125. Fang J., et al. HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: in vitro and in vivo anticancer effect. Eur. J. Pharm. Biopharm. 2012, 81(3):540-547.
126. Nakamura H., et al. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J. Control. Release 2011, 155(3):367-375.
127. Kinobe R.T., Dercho R.A., Nakatsu K. Inhibitors of the heme oxygenase - carbon monoxide system: on the doorstep of the clinic?. Can. J. Physiol. Pharmacol. 2008, 86(9):577-599.
128. Salerno L., et al. Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines. Eur. J. Med. Chem. 2015, 96:162-172.
129. Salerno L., et al. Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties. Bioorg. Med. Chem. 2013, 21(17):5145-5153.
130. Frezza C., et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011, 477(7363):225-228.
131. Linehan W.M., Rouault T.A. Molecular pathways: fumarate hydratase-deficient kidney cancer-targeting the Warburg effect in cancer. Clin. Cancer Res. 2013, 19(13):3345-3352.
132. Isaacs J.S., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8(2):143-153.
133. Sudarshan S., Linehan W.M., Neckers L. HIF and fumarate hydratase in renal cancer. Br. J. Cancer 2007, 96(3):403-407.
134. Nam S.Y., Sabapathy K. p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1. Oncogene 2011, 30(44):4476-4486.
135. Lin P.H., Lan W.M., Chau L.Y. TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation. Oncogene 2013, 32(18):2325-2334.
136. Mayerhofer M., et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008, 111(4):2200-2210.
137. Tibullo D., et al. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Curr. Pharm. Des. 2013, 19(15):2765-2770.
138. Lee J.G., et al. Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. Proteomics 2013, 13(23-24):3554-3562.
139. Do M.T., et al. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol. Appl. Pharmacol. 2013, 271(2):229-238.
140. Chen C.H., et al. Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J. Mol. Med. (Berl.) 2011, 89(3):303-315.
141. Dulak J., Jozkowicz A. Novel faces of heme oxygenase-1: mechanisms and therapeutic potentials. Antioxid. Redox Signal. 2014, 20(11):1673-1676.
142. Otterbein L.E., et al. Heme oxygenase-1 and carbon monoxide modulate DNA repair through ataxia-telangiectasia mutated (ATM) protein. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(35):14491-14496.
143. Zhang Y., et al. Lung endothelial HO-1 targeting in vivo using lentiviral miRNA regulates apoptosis and autophagy during oxidant injury. FASEB J. 2013, 27(10):4041-4058.
144. Yang Y., et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet. Cytogenet. 2010, 196(1):45-55.
145. Wong R.J., et al. In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins. J. Perinatol. 2011, 31(Suppl. 1):S35-S41.
146. Gleixner K.V., et al. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr. Cancer Drug Targets 2009, 9(5):675-689.
147. Rahman M.N., et al. Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds. J. R. Soc. Interface 2013, 10(78):20120697.
148. Cuturi M.C., et al. RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: analysis of its mechanism of action. Mol. Med. 1999, 5(12):820-832.
149. Sass G., et al. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int. J. Cancer 2008, 123(6):1269-1277.
150. Stachurska A., et al. Cross-talk between microRNAs, nuclear factor E2-related factor 2, and heme oxygenase-1 in ochratoxin A-induced toxic effects in renal proximal tubular epithelial cells. Mol. Nutr. Food Res. 2013, 57(3):504-515.